Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1Gynecologic 1

Conditions

Obesity 5Polycystic Ovary Syndrome 3Overweight 1Neoplasms 1Metabolic Syndrome 1Inflammation 1Endometrial Neoplasms 1Endometrial Hyperplasia 1Dyslipidemias 1

Interventions

Exercise 6Nutrition Assessment 4Counseling 4Methods 3Caloric Restriction 3Tirzepatide 2Resistance Training 2Naltrexone 2Metformin 2Megestrol Acetate 2Exenatide 2Educational Status 2Early Intervention, Educational 2Diet 2Cognitive Behavioral Therapy 2Bupropion 2Blood Specimen Collection 2semaglutide 1licogliflozin 1bupropion hydrochloride, naltrexone hydrochoride drug combination 1Ursodeoxycholic Acid 1Urine Specimen Collection 1Trehalase 1Tablets 1Standard of Care 1Psychology, Positive 1Propofol 1Progestins 1Patient Navigation 1Motivational Interviewing 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Overweight × semaglutide × Other × Clear all
NCT07462663 2026-05-13

SHAPE-ENDO

Hospital Universitari de Bellvitge

Phase 4 Not yet recruiting
82 enrolled
GynecologicOther

Endometrial Hyperplasia, Neoplasms, Obesity, Endometrial Neoplasms, Overweight

Data powered by HemOnc (CC BY 4.0) Colophon âš¡